Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Adial Pharmaceuticals, Inc. ADIL NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$8.00
+406.3%

Adial Pharmaceuticals, Inc. (ADIL) is a Biotechnology company in the Healthcare sector, currently trading at $1.58. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ADIL = $8 (+406.3% upside).

Valuation: ADIL trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $8M (loss), growing at -1.3%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $5M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 4.42 (strong liquidity). Debt-to-assets is 0%. Total assets: $7M.

Analyst outlook: 3 / 3 analysts rate ADIL as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$8.00
▲ 406.33% Upside
Average Price Target
The 12-month price target for Adial Pharmaceuticals, Inc. is $8.00.

ADIL SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ADIL

✓
VALUE Pass
100/100
ADIL trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Analyst consensus target is $8, implying +406.3% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ADIL: +0%/yr revenue is, -1.3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ADIL: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 4.42 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ADIL: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 3 / 3 analysts rate ADIL as buy (100%). Analyst consensus target is $8 (+406.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.54-30.25
Volume57.4K
Avg Volume (30D)94.85K
Market Cap$1.52M
Beta (1Y)1.40
Share Statistics
EPS (TTM)-11.93
Shares Outstanding$668.63K
IPO Date2018-07-27
Employees5
CEOCary John Claiborne
Financial Highlights & Ratios
Gross Profit$-565.00
EBITDA$-7.8M
Net Income$-7.98M
Operating Income$-7.8M
Total Cash$5.88M
Net Debt$-5.88M
Total Assets$6.67M
Price / Earnings (P/E)-0.1
Analyst Forecast
1Y Price Target$8.00
Target High$8.00
Target Low$8.00
Upside+406.3%
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS00688A3041

Price Chart

Track all markets on TradingView
ADIL
Adial Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.54 52WK RANGE 30.25

People Also View

CBIO
CBIO
Catalyst Biosciences, Inc.
$19.52
+8.50%
 BNTC
BNTC
Benitec Biopharma Inc.
$13.25
+10.42%
 TNXP
TNXP
Tonix Pharmaceuticals Holding Corp.
$13.35
+2.85%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 RNXT
RNXT
RenovoRx, Inc.
$1.03
+0.98%
 ONTX
ONTX
Onconova Therapeutics, Inc.
$1.00
-0.47%
 NRBO
NRBO
NeuroBo Pharmaceuticals, Inc.
$2.36
+0.00%
 AEZS
AEZS
Aeterna Zentaris Inc.
$5.72
+2.14%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message